Multifunctional, Nanoparticle-Based, Therapies for the Treatment of Periodontal D

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$149,844.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
1R43DE021290-01A1
Award Id:
n/a
Agency Tracking Number:
R43DE021290
Solicitation Year:
2011
Solicitation Topic Code:
NIDCR
Solicitation Number:
PA10-050
Small Business Information
1699 LAKE AVE., B59, MC 01720, ROCHESTER, NY, 14650-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
828749759
Principal Investigator:
JOSEPHBRINGLEY
(585) 402-1130
joebringley@transparentnano.com
Business Contact:
JOSEPHBRINGLEY
(585) 402-1130
joebringley@transparentnano.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to provide improved therapies for the treatment of periodontal disease. Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people.1-12 In severe cases, periodontal disease can lead to a failure of the underlying bone structure and necessitate surgical extraction and replacement of the teeth. In the U.S alone, the cost of treating periodontal disease was estimated at 19 billion dollars annually in 19984. The innovation proposed is to produce multifunctional, surface-modified nanoparticle carriers that are designed to bind robustly to hard tissue surfacesand bacterial biofilms, and may deliver multiple therapeutic payloads. Because the nanoparticles may bind to tissue surfaces and to bacterial biofilms, the carriers may have substantive (long lasting) therapeutic effects within the periodontal pocket, a major shortcoming of current therapies. The ability to localize and chemically attach the drug-carrier within the periodontium is a major advantage of the proposed innovation, since conventional therapies all suffer from the fact that the drugs are rapidlycleared by the turnover of gingival crevicular fluid (saliva).7 The proposed innovation, if successful, will be capable of managing multiple therapeutic chemistries and deliver them to the periodontal pocket and gingival tissues at efficacious levels overan extended period of time, without repeated intervention from a clinician. PUBLIC HEALTH RELEVANCE: Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people. This SBIR seeks to overcome the shortcomings of current therapies for periodontal disease, and to provide a therapy that is capable of managing multiple therapeutic chemistries, delivering them to disease sites over an extended period of time, without the repeated intervention from a clinician.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government